285 related articles for article (PubMed ID: 7525924)
1. Non-N-methyl-D-aspartate receptor antagonism by 3-N-substituted 2,3-benzodiazepines: relationship to anticonvulsant activity.
Donevan SD; Yamaguchi S; Rogawski MA
J Pharmacol Exp Ther; 1994 Oct; 271(1):25-9. PubMed ID: 7525924
[TBL] [Abstract][Full Text] [Related]
2. Protection against non-NMDA receptor-mediated excitotoxicity by GYKI 52466 in mature telencephalic cultures of the rat.
Kovács AD; Egyed A
Neurobiology (Bp); 1996; 4(1-2):59-72. PubMed ID: 9116695
[TBL] [Abstract][Full Text] [Related]
3. The new 2,3-benzodiazepine derivative EGIS-8332 inhibits AMPA/kainate ion channels and cell death.
Vegh MG; Kovács AD; Kovács G; Szabó G; Tihanyi K; Hársing LG; Lévay G
Neurochem Int; 2007 Feb; 50(3):555-63. PubMed ID: 17147974
[TBL] [Abstract][Full Text] [Related]
4. Differential antagonism of alpha-amino-3-hydroxy-5-methyl-4- isoxazolepropionic acid-preferring and kainate-preferring receptors by 2,3-benzodiazepines.
Wilding TJ; Huettner JE
Mol Pharmacol; 1995 Mar; 47(3):582-7. PubMed ID: 7700255
[TBL] [Abstract][Full Text] [Related]
5. 3,5-Dihydro-4H-2,3-benzodiazepine-4-thiones: a new class of AMPA receptor antagonists.
Chimirri A; De Sarro G; De Sarro A; Gitto R; Quartarone S; Zappalà M; Constanti A; Libri V
J Med Chem; 1998 Aug; 41(18):3409-16. PubMed ID: 9719593
[TBL] [Abstract][Full Text] [Related]
6. Interactions among GYKI-52466, cyclothiazide, and aniracetam at recombinant AMPA and kainate receptors.
Johansen TH; Chaudhary A; Verdoorn TA
Mol Pharmacol; 1995 Nov; 48(5):946-55. PubMed ID: 7476926
[TBL] [Abstract][Full Text] [Related]
7. 1-Aryl-3,5-dihydro-4H-2,3-benzodiazepin-4-ones: novel AMPA receptor antagonists.
Chimirri A; De Sarro G; De Sarro A; Gitto R; Grasso S; Quartarone S; Zappalà M; Giusti P; Libri V; Constanti A; Chapman AG
J Med Chem; 1997 Apr; 40(8):1258-69. PubMed ID: 9111300
[TBL] [Abstract][Full Text] [Related]
8. Interaction of GYKI 52466, a selective non-competitive antagonist of AMPA/kainate receptors, with conventional antiepileptic drugs in amygdala-kindled seizures in rats.
Borowicz KK; Duda AM; Kleinrok Z; Czuczwar SJ
Pol J Pharmacol; 2001; 53(2):101-8. PubMed ID: 11787948
[TBL] [Abstract][Full Text] [Related]
9. Synthesis and anticonvulsant activity of novel and potent 2,3-benzodiazepine AMPA/kainate receptor antagonists.
Grasso S; De Sarro G; De Sarro A; Micale N; Zappalà M; Puia G; Baraldi M; De Micheli C
J Med Chem; 1999 Oct; 42(21):4414-21. PubMed ID: 10543885
[TBL] [Abstract][Full Text] [Related]
10. Comparative patch clamp studies on the kinetics and selectivity of glutamate receptor antagonism by 2,3-dihydroxy-6-nitro-7-sulfamoyl-benzo(F)quinoxaline (NBQX) and 1-(4-amino-phenyl)-4-methyl-7,8-methyl-endioxyl-5H-2,3-benzodiaze pine (GYKI 52466).
Parsons CG; Gruner R; Rozental J
Neuropharmacology; 1994 May; 33(5):589-604. PubMed ID: 7523977
[TBL] [Abstract][Full Text] [Related]
11. Synthesis of 7,8-(methylenedioxy)-1-phenyl-3,5-dihydro-4H-2, 3-benzodiazepin-4-ones as novel and potent noncompetitive AMPA receptor antagonists.
Wang Y; Konkoy CS; Ilyin VI; Vanover KE; Carter RB; Weber E; Keana JF; Woodward RM; Cai SX
J Med Chem; 1998 Jul; 41(14):2621-5. PubMed ID: 9651166
[TBL] [Abstract][Full Text] [Related]
12. GYKI 52466, a 2,3-benzodiazepine, is a highly selective, noncompetitive antagonist of AMPA/kainate receptor responses.
Donevan SD; Rogawski MA
Neuron; 1993 Jan; 10(1):51-9. PubMed ID: 7678966
[TBL] [Abstract][Full Text] [Related]
13. Some central effects of GYKI 52466, a non-competitive AMPA receptor antagonist.
Maj J; Rogóz Z; Skuza G; Kołodziejczyk K
Pol J Pharmacol; 1995; 47(6):501-7. PubMed ID: 8868372
[TBL] [Abstract][Full Text] [Related]
14. Negative allosteric modulation of wild-type and mutant AMPA receptors by GYKI 53655.
Partin KM; Mayer ML
Mol Pharmacol; 1996 Jan; 49(1):142-8. PubMed ID: 8569699
[TBL] [Abstract][Full Text] [Related]
15. Pharmacological characterization of the competitive GLUK5 receptor antagonist decahydroisoquinoline LY466195 in vitro and in vivo.
Weiss B; Alt A; Ogden AM; Gates M; Dieckman DK; Clemens-Smith A; Ho KH; Jarvie K; Rizkalla G; Wright RA; Calligaro DO; Schoepp D; Mattiuz EL; Stratford RE; Johnson B; Salhoff C; Katofiasc M; Phebus LA; Schenck K; Cohen M; Filla SA; Ornstein PL; Johnson KW; Bleakman D
J Pharmacol Exp Ther; 2006 Aug; 318(2):772-81. PubMed ID: 16690725
[TBL] [Abstract][Full Text] [Related]
16. Novel systemically active antagonists of the glycine site of the N-methyl-D-aspartate receptor: electrophysiological, biochemical and behavioral characterization.
Parsons CG; Danysz W; Quack G; Hartmann S; Lorenz B; Wollenburg C; Baran L; Przegalinski E; Kostowski W; Krzascik P; Chizh B; Headley PM
J Pharmacol Exp Ther; 1997 Dec; 283(3):1264-75. PubMed ID: 9400002
[TBL] [Abstract][Full Text] [Related]
17. Novel potent AMPA/kainate receptor antagonists: synthesis and anticonvulsant activity of a series of 2-[(4-alkylsemicarbazono)-(4-amino-phenyl)methyl]-4,5-methylenedioxyphenylacetic acid alkyl esters.
Micale N; Zappalà M; Grasso S; Puja G; De Sarro G; Ferreri G; De Sarro A; Toma L; De Micheli C
J Med Chem; 2002 Sep; 45(20):4433-42. PubMed ID: 12238923
[TBL] [Abstract][Full Text] [Related]
18. Allosteric interactions between cyclothiazide and AMPA/kainate receptor antagonists.
Yamada KA; Turetsky DM
Br J Pharmacol; 1996 Apr; 117(8):1663-72. PubMed ID: 8732274
[TBL] [Abstract][Full Text] [Related]
19. SPD 502: a water-soluble and in vivo long-lasting AMPA antagonist with neuroprotective activity.
Nielsen EO; Varming T; Mathiesen C; Jensen LH; Moller A; Gouliaev AH; Wätjen F; Drejer J
J Pharmacol Exp Ther; 1999 Jun; 289(3):1492-501. PubMed ID: 10336544
[TBL] [Abstract][Full Text] [Related]
20. 5-(N-oxyaza)-7-substituted-1,4-dihydroquinoxaline-2,3-diones: novel, systemically active and broad spectrum antagonists for NMDA/glycine, AMPA, and kainate receptors.
Cai SX; Huang JC; Espitia SA; Tran M; Ilyin VI; Hawkinson JE; Woodward RM; Weber E; Keana JF
J Med Chem; 1997 Oct; 40(22):3679-86. PubMed ID: 9357535
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
